Recent studies demonstrated that DANCR facilitated malignancy of prostate cancer by targeting miR-185-5p [13], suggesting that blocking the DANCR-mediated molecular signaling pathways may contribute to chemotherapy of PCa. The gene discussed is DANCR; the disease is prostate carcinoma.